药学学报, 2018, 53(6): 920-928
引用本文:
王伽伯, 张乐, 郭玉明, 柏兆方, 肖小河. 中药药源性肝损伤因果关系的评价策略和方法[J]. 药学学报, 2018, 53(6): 920-928.
WANG Jia-bo, ZHANG Le, GUO Yu-ming, BAI Zhao-fang, XIAO Xiao-he. Causality assessment strategies and methods for Chinese medicines-induced liver injury[J]. Acta Pharmaceutica Sinica, 2018, 53(6): 920-928.

中药药源性肝损伤因果关系的评价策略和方法
王伽伯1, 张乐1, 郭玉明1, 柏兆方1, 肖小河2
1. 中国人民解放军第三○二医院 全军中医药研究所, 北京 100039;
2. 中国人民解放军第三○二医院 中西医结合诊疗与研究中心, 北京 100039
摘要:
中药药源性肝损伤是中药临床应用中常见的严重不良反应之一,一直困扰着中药新药研发、临床安全用药及产业化发展。阐明肝损伤与中药之间的因果关系是极具挑战的国际性难题,也是正确认识中药安全性问题的前提和关键。然而,由于中药自身的复杂性以及临床上影响中药药源性肝损伤的因素众多,患者肝损伤与中药之间的因果关系更是难以评价;同时现有的评价方法主要是针对临床诊疗设计的,不适用于中药新药的研发以及上市后再评价。为此,本文综述分析了国内外主要因果关系评价方法的类型和优缺点,进一步以新药研发中的药源性肝损伤因果关系评价为目标,结合中药复杂性特点,提出基于整合证据链的中药药源性肝损伤因果关系评价新策略和新方法,以期科学厘定患者肝损伤与中药之间的因果关系,提高中药新药研发成功率,更好地发现、规避和防范中药药源性肝损伤风险,为公众健康服务。
关键词:    中药      药源性肝损伤      因果关系评价      整合证据链     
Causality assessment strategies and methods for Chinese medicines-induced liver injury
WANG Jia-bo1, ZHANG Le1, GUO Yu-ming1, BAI Zhao-fang1, XIAO Xiao-he2
1. China Military Institute of Chinese Medicines, 302 Military Hospital of China, Beijing 100039, China;
2. Integrative Medicine Center, 302 Military Hospital of China, Beijing 100039, China
Abstract:
Chinese medicines (CM)-induced liver injury is one of the severe adverse drug reactions (ADRs) in clinical application, which restricts new drug research and development (R&D), clinical safe usage and industry development of CM. The issue, to elucidate the causality between liver injury and CM, is either a globally challenging problem or the precondition of CM safety evaluation. However, owing to the complexicity of CM and various influencing factors to CM-induced liver injury, the causality assessment for CM is much difficult, compared to synthetic drugs. Besides, the current assessment methods, primarily designed for clinical diagnosis, are difficult to be used in new drug R&D of CM. Hereinto, we reviewed the current ADR causality methods and proposed a new strategy called integrated evidence chain-based causality assessment method for CM-induced liver injury. The new causality method is designed for new drug R&D based on the complexicity of CM, to provide methodology in scientific assessment of causality of CM-induced liver injury and to promote success rate of new drug R&D. The new method could also raise our ability to find, avoid and prevent the risk of CM-induced liver injury.
Key words:    Chinese medicines    drug-induced liver injury    causality assessment    integrated evidence chain   
收稿日期: 2018-05-14
DOI: 10.16438/j.0513-4870.2018-0439
基金项目: 国家自然科学基金重点项目(81630100);国家公益性行业专项课题资助项目(201507004-04).
相关功能
PDF(271KB) Free
打印本文
0
作者相关文章
王伽伯  在本刊中的所有文章
张乐  在本刊中的所有文章
郭玉明  在本刊中的所有文章
柏兆方  在本刊中的所有文章
肖小河  在本刊中的所有文章

参考文献:
[1] Björnsson ES, Bergmann OM, Björnsson HK, et al. Inci-dence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.[J]. Gastroenterology, 2013, 144:1419-1425.
[2] Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Dis, 2002, 22:145-155.
[3] Li L, Jiang W, Wang J. Clinical analysis of 275 cases of acute drug-induced liver disease[J]. Front Med, 2007, 1:58-61.
[4] Jung KA, Min HJ, Yoo SS, et al. Drug-induced liver injury:twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum thumb[J]. Gut and Liver, 2011, 5:493-499.
[5] Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements[J]. Semin Liver Dis, 2014, 34:172.
[6] Teschke R, Frenzel C, Glass X, et al. Herbal hepatotoxicity:a critical review[J]. Brit J Clin Pharmacol, 2013, 75:630- 636.
[7] Song HB, Han L. Epidemiologic characteristics, risk factors and safetyevaluation of traditional Chinese medicine induced liver injury[J]. Chin J Pharmacol Toxicol (中国药理学与毒理学杂志), 2016, 30:291-305.
[8] China Association of Chinese Medicine. Guideline for Diagnosisand Treatment of Herb-Induced Liver Injury (T/CACM 005-2016) (中草药相关肝损伤临床诊疗指南)[S]. Beijing:Chinese Press of Traditional Chinese Medicine, 2016:4.
[9] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109:950-966.
[10] Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region [J]. BMJ, 1999, 319:1541.
[11] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury:the dilin prospective study[J]. Gastroenterology, 2015, 148:1340- 1352(e7).
[12] Zhu Y, Niu M, Chen J, et al. Hepatobiliary and pancreatic:comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients[J]. J Gastroenterol Hepatol, 2016, 31:1476-1482.
[13] Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:an international collaborative effort[J]. Hepatology, 2018. DOI:10.1002/hep.29802.
[14] Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury[J]. Proc Natl Acad Sci U S A, 2009, 106:4402-4407.
[15] Starckx S, Batheja A, Verheyen GR, et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats[J]. Toxicol Pathol, 2013, 41:795-804.
[16] Yu YC, Mao YM, Chen CW. Guidelines for the management of drug-induced liver injury[J]. Chin Hepatol (肝脏), 2015, 23:1752-1769.
[17] Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis[J]. Eur J Clin Pharmacol, 2006, 62:423-429.
[18] Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity:contribution of UGT2B7, CYP2C8, and ABCC2 genotypes[J]. Gastroenterology, 2007, 132:272-281.
[19] Luyendyk JP, Lehmanmckeeman LD, Nelson DM, et al. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model:comparison with famotidine[J]. Toxicol Sci, 2006, 90:569- 585.
[20] Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity[J]. Toxicol Sci, 2010, 118:7-18.
[21] Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class Ⅱ genotype in susceptibility and resistance to co-amoxiclav-induced liver injury[J]. J Hepatol, 2010, 53:1049-1053.
[22] Li CY, Li YF, Tu C, et al. The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model[J]. Acta Pharm Sin (药学学报), 2015, 50:28-33.
[23] Tang JF, Wang XY, Wen Q, et al. Idiosyncratic hepatotoxicity evaluation of Zhuangguguanjie wan mediated by immune stress[J]. Acta Pharm Sin (药学学报), 2017, 52:1033-1040.
[24] Zhang P, Li MH, Liu W, et al. National quality evaluation and analysis of Chinese medicinal materials and decoction pieces in 2015[J]. Chin Med Mat (中药材), 2016, 39:2400- 2406.
[25] Xu J, Zheng WK, Li P, et al. Clinical analysis of 20 cases with gynura segetum-induced hepatic sinusoidal obstruction syndrome[J]. Chin Hepatol (肝脏), 2016, 21:905-907.
[26] Ma SC, Jin HY, Liu LN, et al. Risk cntrol of exogenous harmful residues in traditional Chinese medicines[J]. Chin Pharm J (中国药学杂志), 2015, 50:99-103.
[27] Kong XY, Chen Q, Wu X, et al. The research progress of interaction between Chinese and Western medicine combination[J]. J Nanjing Univ Tradit Chin Med (南京中医药大学学报), 2018, 34:5-11.
[28] Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions:a systematic review[J]. Drug Safety, 2008, 31:21-37.
[29] Wei X, Xie YM. Principle of adverse drug reaction causality judgement of causality assessment method both in China and interpretation and abroad[J]. China J Chin Ma-ter Med (中国中药杂志), 2012, 37:2744-2747.
[30] Hoskins RE, Mannino S. Causality assessment of adverse drug reactions using decision support and informatics tools[J]. Pharmacoepidem Drug Saf, 1992, 1:235-249.
[31] Arimone Y, Bégaud B, Miremont-Salamé G, et al. A new method for assessing drug causation provided agreement with experts' judgment[J]. J Clin Epidemiol, 2006, 59:308- 314.
[32] Tantikul C, Dhana N, Jongjarearnprasert K, et al. The utility of the World Health Organization-the Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children[J]. Asian Pac J Allergy, 2008, 26:77-82.
[33] Venulet J. Aspects of standardization as applied to the assessment of drug-event associations[J]. Drug Inf J, 1984, 18:199-210.
[34] Pande S. Causality or relatedness assessment in adverse drug reaction and its relevance in dermatology[J]. Indian J Dermatol, 2018, 63:18-21.
[35] Hutchinson TA. Computerized Bayesian ADE assessment [J]. Drug Inf J, 1991, 25:235-241.
[36] Théophile H, Arimone Y, Miremontsalamé G, et al. Com-parison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions:an assessment using reports made to a French pharmacovigilance centre[J]. Drug Safety, 2010, 33:1045-1054.
[37] Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries[J]. J Clin Epidemiol, 1993, 46:1323-1330.
[38] Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - Ⅱ. An original model for validation of drug causality assessment methods:case reports with positive rechallenge[J]. J Clin Epidemiol, 1993, 46:1331- 1336.
[39] Danan G, Teschke R. RUCAM in drug and herb induced liver injury:the update[J]. Int J Mol Sci, 2015, 17:14-46.
[40] Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis[J]. Hepatology, 1997, 26:664-669.
[41] Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30:239-245.
[42] Yu YC, Fan Y. Advances in Roussel Uclaf causality assessment method for diagnosis of drug-induced liver injury and its comparisonwith structured expert opinion process[J]. J Clin Hepatol (临床肝胆病杂志), 2016, 32:1706-1713.
[43] Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process:comparison to the Roussel-Uclaf causality assessment method[J]. Hepatology, 2010, 51:2117-2126.
[44] Wang JB, Li CY, Zhu Y, et al. Integrated evidence chain- based identification of Chinese herbal medicine-induced hepatotoxicity and rationalusage:exemplification by Polygonum Multiflorum (He shouwu) (in Chinese)[J]. Chin Sci Bull (科学通报), 2016, 61:971-980.
[45] Chèze M, Duffort G, Deveaux M, et al. Hair analysis by liquid chromatography-tandem mass spectrometry in toxicological investigation of drug-facilitated crimes:report of 128 cases over the period June 2003-May 2004 in metropolitan Paris[J]. Forensic Sci Int, 2005, 153:3-10.
[46] Kintz P, Salomone A, Vincenti M. Hair Analysis in Clinical and Forensic Toxicology[M]. London:Academic Press, 2015.
[47] Ye HY, Zheng SQ, Liang C, et al. Analysis of seven drugs in human hair by hybrid linear ion Trap/orbitrap mass spectrometry[J]. Chin J Anal Chem (分析化学), 2012, 40:1674-1679.
[48] Wang JB, Cui HR, Bai ZF, et al. Precision medicine-oriented safety assessment strategy for traditional Chinese medicines:disease-syndrome-based toxicology[J]. Acta Pharm Sin (药学学报), 2016, 51:1681-1688.
[49] Liu C, Fan H, Li Y, et al. Research advances on hepatotoxicity of herbal medicines in China[J]. Biomed Res Int, 2016, 2016:1-14.
[50] Zhu Y, Liu SH, Wang JB, et al. Clinical analysis of drug- induced liver injury caused by Polygonum multiflorum and its preparations[J]. Chin J Integr Tradit West Med (中国中西医结合杂志), 2015, 35:1442-1447.
[51] Wang J, Jiang Z, Ji J, et al. Evaluation of hepatotoxicity and cholestasis in rats treated with EtOH extract of Fructus Psoraleae.[J]. J Ethnopharmacol, 2012, 144:73-81.
[52] Ng A, Poon SL, Huang MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia[J]. Sci Transl Med, 2017, 9:eaan6446.